title: XIAP-mediated neuroprotection in retinal ischemia.
abstract: Retinal ischemia results in the loss of vision in a number of ocular diseases including acute glaucoma, diabetic retinopathy, hypertensive retinopathy and retinal vascular occlusion. Recent studies have shown that most of the neuronal death that leads to loss of vision results from apoptosis. XIAP-mediated gene therapy has been shown to protect a number of neuronal types from apoptosis but has never been assessed in retinal neurons following ischemic-induced cell death. We injected an adeno-associated viral vector expressing XIAP or GFP into rat eyes and 6 weeks later, rendered them ischemic by raising intraocular pressure. Functional analysis revealed that XIAP-treated eyes retained larger b-wave amplitudes than GFP-treated eyes up to 4 weeks post-ischemia. The number of cells in the inner nuclear layer (INL) and the thickness of the inner retina were significantly preserved in XIAP-treated eyes compared to GFP-treated eyes. Similarly, there was no significant reduction in optic nerve axon numbers in XIAP-treated eyes. There were also significantly fewer TUNEL (TdT-dUTP terminal nick end labeling) positive cells in the INL of XIAP-treated retinas at 24 h post-ischemia. Thus, XIAP-mediated gene therapy imparts both functional and structural protection to the retina after a transient ischemic episode.
authors.affiliation: University of Ottawa Eye Institute, Ottawa, Ontario, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Renwick
authors.forename: M A
authors.initials: MA
authors.lastname: Narang
authors.forename: S G
authors.initials: SG
authors.lastname: Coupland
authors.forename: J Y
authors.initials: JY
authors.lastname: Xuan
authors.forename: A N
authors.initials: AN
authors.lastname: Baker
authors.forename: J
authors.initials: J
authors.lastname: Brousseau
authors.forename: D
authors.initials: D
authors.lastname: Petrin
authors.forename: R
authors.initials: R
authors.lastname: Munger
authors.forename: B C
authors.initials: BC
authors.lastname: Leonard
authors.forename: W W
authors.initials: WW
authors.lastname: Hauswirth
authors.forename: R G
authors.initials: RG
authors.lastname: Korneluk
authors.forename: C
authors.initials: C
authors.lastname: Tsilfidis
mesh_terms: D000818:Animals; D002452:Cell Count; D000229:Dependovirus / Q000235:genetics; D004596:Electroretinography; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D049452:Green Fluorescent Proteins / Q000235:genetics; D020287:In Situ Nick-End Labeling; D007267:Injections; D007511:Ischemia / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008297:Male; D009474:Neurons / Q000378:metabolism / Q000473:pathology*; D009900:Optic Nerve / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000378:metabolism / Q000473:pathology*; D012164:Retinal Diseases / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000235:genetics* / Q000378:metabolism
chemical_list: D051636:X-Linked Inhibitor of Apoptosis Protein; D049452:Green Fluorescent Proteins